-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Xilio Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q3 2020 to Q3 2025.
- Xilio Therapeutics, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$1.93M, a 86.9% increase year-over-year.
- Xilio Therapeutics, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$43.8M, a 32.7% increase year-over-year.
- Xilio Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$60.6M, a 23.4% increase from 2023.
- Xilio Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$79.1M, a 11.2% increase from 2022.
- Xilio Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$89.1M, a 18.8% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)